Biological and Histopathological Studies on the Effect of the Antibiotic Clindamycin on Albino Rat Fetuses
Keywords:
Dalacin-C, Teratogenicity, GestationAbstract
Dalacin-C (clindamycin palmitatehydrochoride) is indicated in the treatment of serious infections due to sensetiveanaerobic bacteria and gram- positive aerobic organisms. The aim of this study was to evaluate the teratogenic effects of Dalacin-C on pregnant rats and their fetuses. Pregnant albino rats (Rattusnorvegicus) were administrated daily oral doses of 185mg/kg of Dalacin-C from the5th- 19thday of gestation. The animals were sacrificed at the 20th day of gestation. Fetuses were removed from the uterus and evaluated for mortality rate, growth parameters, morphological and skeletal malformation as well as histological study of liver, kidney and brain. Results showed significant reduction in weight gain of pregnant rats and decreased placental weight of pregnant rats treated with Dalacin-C. Fetal growth retardation during gestational period was recorded. Hematomas and anomalies of limbswere noticed morphologically in the recorded. These abnormalities included weak ossification of the skull bones roof. Histopathological studies of fetuses during gestation revealed Changes in liver histology such as degeneration of the cytoplasm of hepatocytes and increases in the number of megakaryocytes were seen, revealed degeneration in the tubular lining epithelium with swelling in the endothelial cells lining the tufts of the glomeruli within the Bowman's capsule while in the brain tissue no histopathological alterations as recorded following Dalacin-Cadministration. Our findings suggest the need for great caution to handle Dalacin-Cespecially during pregnancy.
Â
References
• Bancroft, J.D. and Gamble, M. (2002): Theory and practice of histological techniques. 5th ed. Churchill Livingstone: London, UK.
• Brandon B.P., Christopher M. B., Brooke G., Kayla R. S., Lea S. E. and Milena M. (2015): A Review of Antibiotic Use in Pregnancy.Pharmacotherapy, 35(11):1052–1062.
• Burt, C. C. and Durbridge, J. (2009): Management of cardiac disease in pregnancy, Continuing Education in Anaesthesia, Critical Care and Pain, 9 (2): 44–47.
• Deinz, E., Dural, K. and Tuncay, P. (1995): Visualization of the fetal skeletal system by double staining with alizarin red and alcian blue. Gazi Medical Journal, 6: 55-58.
• Farris, EJ. (Ed.). The care and breeding of laboratory animals. 7 ed. New York: John Willey and Sons, 1967.
• Joglar, J. A. and Page, R. L. (2014): Management of arrhythmia syndromes during pregnancy, Current Opinion in Cardiology. 29 (1): 36–44.
• Lapin B., Piorkowski J., Ownby D., et al. (2015): Relationship between prenatal antibiotic use and asthma in at-risk children. Ann. Allergy Asthma Immunol.,3:203–7.
• Moore, KL.The developing human. 4 ed. Philadelphia: WBSaunder, 1988.
• Mueller N.T., Whyatt R., Hoepner L., et al. (2015): Prenatal exposure toantibiotics, cesarean section and risk of childhood obesity. Int. J.Obes. (Lond), 39:665–70.
• Nahum, G.G., Uhl, K. and Kennedy, D.L. (2006):Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstetrics & Gynecology, 107: 1120‑1138.
• O’Rahilly, R.(2001): Human Embryology & Teratology, Wiley-Liss,New York, NY, USA, 3rd edition.
• Sadler, TW.(2000):(Ed.). Langman’s medical embryology. 8 ed. Baltimore: Williams and Wilkins.
• Schlegel, P. N., Chang, T. S. K. and Marshall, F. F. (1991): Antibiotics: potential hazards tomale fertility,†Fertility and Sterility. 55 (2): 235–242.
• Somer, GF. Thalidomide and congenital abnormalities.Lancet. 1962, vol. 1, p. 912-913.
• Stensballe L.G., Simonsen J., Jensen S.M., Bonnelykke K. and Bisgaard H. (2013): Use of antibiotics during pregnancy increases the risk of asthma in early childhood. J.Pediatr., 4:832–8 e3.
• Thomas M. and Price D. (2003): Prenatal antibiotic exposure and subsequent atopy. Am J.Respir. Crit. Care. Med., 11:1578; author reply 78-9.
• Vidal A.C., Murphy S.K., Murtha A.P., et al. (2013): Associations between antibiotic exposure during pregnancy, birth weight and aberrant methylation at imprinted genes among offspring. Int. J. Obes. (Lond), 7:907–13.
Downloads
Published
Issue
Section
License
- Papers must be submitted on the understanding that they have not been published elsewhere (except in the form of an abstract or as part of a published lecture, review, or thesis) and are not currently under consideration by another journal published by any other publisher.
- It is also the authors responsibility to ensure that the articles emanating from a particular source are submitted with the necessary approval.
- The authors warrant that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required.
- The authors ensure that all the references carefully and they are accurate in the text as well as in the list of references (and vice versa).
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.
